SCHEMBL1783992

SCHEMBL1783992

CC(C)n1cc(I)c2c(N)ncnc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.51
PIK3CA P42336 1/20 0.51
PIK3CB P42338 1/20 0.51
PIK3CG P48736 1/20 0.51
PRKDC P78527 1/20 0.51
KDR P35968 9/20 0.51
RET P07949 8/20 0.51
LCK P06239 6/20 0.50
TEK Q02763 5/20 0.50
SRC P12931 3/20 0.50
ADORA2A P29274 1/20 0.50
ADORA2B P29275 1/20 0.50
ADORA1 P30542 1/20 0.50
PI4KA P42356 1/20 0.50
PI4K2B Q8TCG2 1/20 0.50
PI4K2A Q9BTU6 1/20 0.50
PI4KB Q9UBF8 1/20 0.50
DYRK3 O43781 1/20 0.49
ROCK2 O75116 1/20 0.49
PRKD3 O94806 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30104038 0.89 DYRK3 (0.46) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL24458479 0.86 RET (0.53) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL16236571 0.84 ADORA2A (0.55) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL20162723 0.83 DYRK3 (0.44) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL19732636 0.83 RET (0.49) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL30038177 0.83 DYRK3 (0.44) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL16236508 0.83 RET (0.53) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL2618932 0.81 PIK3CD (0.52) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL16236738 0.81 ADK (0.46) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL6364419 0.80 PIK3CD (0.51) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577249-B2 GCN2 and perk kinase inhibitors and methods of use thereof DECIPHERA PHARMACEUTICALS, LLC (US) 2026-03-17 US disclosed
US-20250154154-A1 SRC INHIBITORS AND USES THEREOF RELAY THERAPEUTICS, INC. 2025-05-15 US disclosed
EP-4440703-A1 HETEROCYCLIC COMPOUNDS AS GCN2 AND PERK KINASE INHIBITORS Deciphera Pharmaceuticals, LLC (US) 2024-10-09 EP disclosed
CN-118715223-A Heterocyclic compounds as GCN2 and PERK kinase inhibitors 德西费拉制药有限责任公司 2024-09-27 CN disclosed
US-20240317758-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2024-09-26 US disclosed
CN-117597346-A NEK7 inhibitors 哈利亚治疗公司 2024-02-23 CN disclosed
EP-4320127-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2024-02-14 EP disclosed
US-11833153-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2023-12-05 US disclosed
US-20230382915-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-11-30 US disclosed
US-20230382915-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-11-30 US disclosed
US-8993580-B2 Benzothiazole kinase inhibitors and methods of use INTELLIKINE LLC (US) 2015-03-31 US disclosed
US-8993580-B2 Benzothiazole kinase inhibitors and methods of use INTELLIKINE LLC (US) 2015-03-31 US disclosed
WO-2014184069-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-11-20 WO disclosed
WO-2014184069-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-11-20 WO disclosed
US-20140235567-A1 5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME LLC 2014-08-21 US disclosed
US-20110124641-A1 BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE INTELLIKINE LLC 2011-05-26 US disclosed
US-20110124641-A1 BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE INTELLIKINE LLC 2011-05-26 US disclosed
US-20110124641-A1 BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE INTELLIKINE LLC 2011-05-26 US disclosed
WO-2009114874-A2 BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE INTELLIKINE, INC. (US) 2009-09-17 WO disclosed
WO-2009114874-A2 BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE INTELLIKINE, INC. (US) 2009-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577249-B2 GCN2 and perk kinase inhibitors and methods of use thereof EIF2AK4, GCN1, MAPKAPK2 PIK3CD 1627/4885PIK3CA 1172/4885PIK3CB 1599/4885
US-11833153-B2 N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors ATF4, MAP3K1, MAP3K6 PIK3CD 425/4885PIK3CA 266/4885PIK3CB 428/4885
US-20110124641-A1 BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE MTOR, PDPK1, PIKFYVE PIK3CD 22/4885PIK3CA 5/4885PIK3CB 10/4885
US-20230382915-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF EIF2AK4, GCN1, EEF2K PIK3CD 1316/4885PIK3CA 696/4885PIK3CB 986/4885
US-20240317758-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 PIK3CD 3293/4885PIK3CA 2437/4885PIK3CB 3583/4885
US-20140235567-A1 5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES NT5C3B, PNP, SLC29A1 PIK3CD 2952/4885PIK3CA 1970/4885PIK3CB 2713/4885
US-20250154154-A1 SRC INHIBITORS AND USES THEREOF SRC, LCK, FYN PIK3CD 223/4885PIK3CA 184/4885PIK3CB 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.